Anxiety, depression, and quality of life in hepatocellular carcinoma treated with drug-eluting microspheres plus lenvatinib: A prospective study

Table 4 Correlation between the Hospital Anxiety and Depression Scale score and quality of life domains at baseline (n = 126)

QLQ-C30/QLQ-HCC18 domain	HADS-A score (r)	P value	HADS-D score (r)	P value
Global health status/QoL	-0.68	< 0.001	-0.71	< 0.001
Physical functioning	-0.61	< 0.001	-0.64	< 0.001
Role functioning	-0.59	< 0.001	-0.62	< 0.001
Emotional functioning	-0.72	< 0.001	-0.75	< 0.001
Social functioning	-0.57	< 0.001	-0.60	< 0.001
Fatigue	0.58	< 0.001	0.63	< 0.001
Pain	0.54	< 0.001	0.57	< 0.001
Nausea and vomiting	0.42	< 0.001	0.45	< 0.001
QLQ-HCC18 nutrition	0.56	< 0.001	0.61	< 0.001
QLQ-HCC18 fatigue	0.60	< 0.001	0.65	< 0.001
QLQ-HCC18 body image	0.52	< 0.001	0.55	< 0.001

HADS-A: Hospital Anxiety and Depression Scale-Anxiety subscale; HADS-D: Hospital Anxiety and Depression Scale-Depression subscale; QLQ-C30: Quality of Life Questionnaire-Core 30; QLQ-HCC18: Quality of Life Questionnaire-Hepatocellular Carcinoma 18; QoL: Quality of life.